ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $37.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on ACAD. Royal Bank of Canada decreased […]

Related Keywords

Canada ,United States ,America ,Robertw Baird ,Markc Schneyer ,Brendan Teehan ,Pharmaceuticals Inc ,Charles Schwab Investment Management Inc ,Securities Exchange Commission ,Royal Bank ,Jpmorgan Chase Co ,Mutual Of America Capital Management ,Northern Trust Corp ,Cantor Fitzgerald ,Pharmaceuticals Daily ,Pharmaceuticals Price Performance ,Qube Research Technologies Ltd ,Morgan Stanley ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,America Capital Management ,Technologies Ltd ,Schwab Investment Management ,Trust Corp ,Acadia Pharmaceuticals ,Nasdaq Acad ,Facad ,Medical ,Reiterated Rating ,